Arizona bats test positive for possibly deadly fungus; wildlife agency seeks public's help
Bats in southeastern Arizona have tested positive for a fungus that poses a threat to the species, prompting wildlife officials to urge the public to report any potential infections.
A bat that was part of the cave myotis species in Fort Huachuca, just west of Sierra Vista, tested positive for a fungus known as Pseudogymnoascus destructans (Pd) that can cause deadly white-nose syndrome (WNS), according to the Arizona Department of Game and Fish.
The positive sample was collected during a June 2024 surveillance when Game and Fish identified a bat with abnormal wing features linked to the disease. The agency later discovered four additional bats, including two from other species, that tested positive for trace amounts of the fungus.
Debbie Brewer, a Game and Fish biologist for the Fort Huachuca area, said monitoring for the Pd has existed in the area since 2014, with positive infections found in 2017, followed by low-level spread in 2021 and 2023.
"Though not unexpected, our 2024 high-level positive detection in cave myotis is highly concerning and should put other land managers in the Southwest on alert that habitat protections for this and other species of bat are warranted," wrote Brewer in a news release.
With the help of citizen scientists: An endangered bat species has been found in Arizona
Pd, which causes white-nose syndrome, is named after the white fungal growth seen on infected bats. Since 2006, the disease has led to the deaths of millions of bats across 40 U.S. states and nine Canadian provinces, according to Game and Fish.
White-nose syndrome does not pose a risk to humans or pets, but human activity is a major concern for bringing fungal spores into cold, humid caves where bats hibernate, and where optimal growing conditions exist for the fungus.
'This disease did not exist when I first began working with bats. To see new threats to our bat populations like this is disturbing," said Angie McIntire, a specialist on Arizona bats for Game and Fish.
A bat infected with WNS may display unusual behavior, which Game and Fish said usually appears like the bat is unable to fly or is perched low on a wall or is on the ground.
The wildlife agency asks the public to help monitor for the disease by reporting any possible cases by email to bats@azgfd.gov, sending a detailed report of the encounter, photos, location and contact information, but also reminds the public to never handle bats.
Game and Fish said since 2019, the fungus has been found in Mohave, Coconino, Yavapai and Cochise counties, and at Grand Canyon National Park. Between 2021 and 2024, a total of eight bats, including cave myotis, southwestern myotis and big brown bats, tested positive for the fungus.
Infections within the cave myotis bat species also have been found nearby in New Mexico and Texas, highlighting to researchers a possible vulnerability among the species for WNS.
Bat season in Arizona: What attracts them and are they dangerous?
Reach reporter Rey Covarrubias Jr. at rcovarrubias@gannett.com. Follow him on X, Threads and Bluesky @ReyCJrAZ.
This article originally appeared on Arizona Republic: Bats in southern Arizona test positive for fungus deadly to species
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Politico
42 minutes ago
- Politico
HHS justifies decision to stop recommending Covid shots during pregnancy with studies supporting the shots' safety
The Department of Health and Human Services is circulating a document on Capitol Hill to explain its decision to remove the Covid-19 vaccine recommendation for pregnant women — citing studies that largely found the shot is safe. The document, which HHS sent to lawmakers days before Secretary Robert F. Kennedy Jr. announced his plan to fire the panel that advises the CDC on immunizations, says that studies have shown that women who got the vaccine during pregnancy had higher rates of various complications. And it claims that 'a number of studies in pregnant women showed higher rates of fetal loss if vaccination was received before 20 weeks of pregnancy,' footnoting a research paper on vaccination during pregnancy. But Dr. Maria P. Velez of McGill University, the lead author of one of the studies, told POLITICO in an email that 'the results of our manuscript were misinterpreted.' The 2023 study shows a slightly higher rate of miscarriages among women who were immunized against Covid-19 during their pregnancies. But, Velez said, that after adjusting for 'variables that can confound a crude association,' like 'age, rurality, neighbourhood income quintile, immigration status, comorbidity' and other factors that could affect the outcome, Canadian researchers found 'no association between SARS-CoV-2 vaccination and an increased risk of miscarriage.' Raw numbers don't account for significant differences among the groups being compared — such as underlying conditions and when during pregnancy the people were vaccinated, said Katelyn Jetelina, an epidemiologist who's consulted for the Centers for Disease Control and Prevention. Scientists, including the Canadian researchers, use statistical methods to adjust for those factors, she said, which is how they determined the vaccine wasn't associated with miscarriage. In a statement, HHS spokesperson Andrew Nixon pointed to the raw study data, which showed a slightly higher rate of miscarriage in the first half of pregnancy for women who were vaccinated against Covid compared with those who weren't. 'The underlying data speaks for itself — and it raises legitimate safety concerns,' he said. 'HHS will not ignore that evidence or downplay early pregnancy loss.' Nixon added that HHS and the CDC encourage people to talk to their providers 'about any personal medical decision.' Vaccine researchers and obstetricians criticized the decision to remove the recommendation for pregnant women, and researchers cited in the HHS document largely dismissed any connection between Covid vaccination and miscarriages. 'Given that COVID-19 infection during pregnancy is associated with serious maternal and neonatal morbidity, the current study can inform healthcare providers, pregnant women and those considering a pregnancy about the safety of SARS-CoV-2 vaccination in relation to miscarriage risk,' Velez and her co-authors wrote in the study. That research was based on health-system data from Ontario, Canada, and aligned with similar population studies in the U.S., Scotland and Norway. Similarly, HHS cited an April 2022 study in its document concerning mRNA vaccination in people undergoing in-vitro fertilization, which also found no adverse effects on conception rates or on early pregnancy outcomes. 'Administration of COVID-19 mRNA vaccines was not associated with an adverse effect on stimulation or early pregnancy outcomes after IVF,' the New York City-based researchers at the Icahn School of Medicine at Mount Sinai and Mount Sinai West hospital wrote in the study. 'Our findings contribute to the growing body of evidence regarding the safety of COVID-19 vaccination in women who are trying to conceive.' The HHS document also includes an incorrect link for that study, instead leading to a different study — also cited in HHS' document — by Israeli researchers that found the vaccine 'appears to be safe during pregnancy,' with no increase in preterm labor or in newborns with low birth weight. That February 2022 study did note a possible increase in preterm birth rates for women vaccinated during the second trimester, and the authors suggested future investigations of outcomes based on the timing of immunization. HHS' assertion about significant risks to pregnant women 'contradicts the bulk of published studies,' said Dr. Paul Offit, an expert who has served as an outside adviser on vaccines to the FDA and the CDC. HHS deviated from past practice when it changed the Covid vaccine guidance last month, announcing the decision without the endorsement of an existing outside panel of expert advisers. Dr. Steven Fleischman, president of the American College of Obstetricians and Gynecologists, told POLITICO at the time that he was disappointed by HHS' decision, and pointed to data showing that newborns can benefit from maternal antibodies from the vaccine for protection from Covid. 'In fact, growing evidence shows just how much vaccination during pregnancy protects the infant after birth, with the vast majority of hospitalized infants less than 6 months of age — those who are not yet eligible for vaccination — born to unvaccinated mothers,' Fleischman said.
Yahoo
an hour ago
- Yahoo
Scientists make jaw-dropping discovery after satellite images reveal what's hiding over a mile beneath Antarctic ice: 'It's like uncovering a time capsule'
Scientists studying the East Antarctic Ice Sheet discovered a 34-million-year-old river-carved landscape hidden under more than a mile of ice, The Brighter Side of News reported. The concealed world offered a unique glimpse into the history and potential future of the critical ice sheet. "It's like uncovering a time capsule," said Stewart Jamieson of Durham University, the study's lead author, per The Brighter Side of News. The preserved landscape, which existed before the formation of the Antarctic sheet ice, spanned nearly 4 million square miles, providing experts with an unprecedented view into the region's geological history. The team used RADARSAT, a Canadian satellite system, to detect the landscape beneath the ice, per The Brighter Side of News. By studying the preserved landscape, researchers can better understand previous cycles of freezing and melting that can be crucial to predicting how future Antarctic ice melt will unfold. Because the Antarctic ice sheets sit on land rather than floating in water like Arctic ice, their melting would have a dramatic impact on sea levels around the world. According to the University of Texas Institute of Geophysics, the basin where the researchers discovered the hidden landscape contained enough ice to raise sea levels by a catastrophic 25 feet or more. Still, the land under the surface of that crucial ice sheet remained more mysterious to researchers than the surface of Mars. "And that's a problem because the landscape controls the way that ice in Antarctica flows, and it controls the way it might respond to past, present, and future climate change," Jamieson told UTIG. Researchers expressed hope that the discovery will lead to similar findings in other regions. "This landscape hanging out there in the middle of the basin is a little bit of an odd phenomenon," said Duncan Young, a research scientist for UTIG. "We're now working to answer why it was preserved and use that knowledge to find others." Combined, the ice sheets of Antarctica and Greenland contain two-thirds of Earth's fresh water, and they are melting at an astounding rate, according to NASA. The Antarctic ice sheet alone is shedding a jaw-dropping 150 billion tons of ice every single year. While studying the potential future impacts of rising global temperatures is important, it is just as important to prevent planet-warming pollution from entering the atmosphere in the first place. By taking steps like installing solar on your home, switching to an electric vehicle, or growing your own food in a home garden, you can do your part to help limit increasing global temperatures and sea-level rises. While these might seem like small things to do in the face of such a momentous challenge, if we multiply those actions by millions or even billions of people, we can make a real difference. Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet.
Yahoo
an hour ago
- Yahoo
MAIA Biotechnology to Present at BIO International Convention 2025
CHICAGO, June 10, 2025--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced its participation in the upcoming BIO (Biotechnology Innovation Organization) International Convention 2025 taking place June 16-19, 2025, in Boston, Massachusetts. MAIA Chairman and CEO Vlad Vitoc, MD, MBA will deliver a presentation featuring the latest findings from the Company's THIO-101 Phase 2 clinical trial evaluating ateganosine (THIO) sequenced with the immune checkpoint inhibitor (CPI) cemiplimab (Libtayo®) in advanced non-small cell lung cancer (NSCLC). Ateganosine is a small molecule telomere-targeting anticancer agent that acts by producing direct telomeric DNA damage and inducing cancer-specific immune responses. THIO-101 is expected to be the first completed clinical study of a telomere-targeting agent in the field of cancer drug discovery and treatment. MAIA recently announced the design for the expansion of the THIO-101 trial, which will further assess the efficacy of treatment in third-line NSCLC patients. Presentation DetailsSession date and time: June 18 at 11:30 AM EDTPresenter: Vlad Vitoc, MD, MBA Registered participants may request a meeting with MAIA management via the BIO Partnering™ platform on the BIO 2025 website. About BIO BIO (Biotechnology Innovation Organization) is the world's largest advocacy association representing biotechnology companies, academic and research institutions, state biotechnology centers, and related organizations across the United States and in more than 30 other nations. About Ateganosine Ateganosine (THIO, 6-thio-dG or 6-thio-2'-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2'-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors. About THIO-101, a Phase 2 Clinical Trial THIO-101 is a multicenter, open-label, dose finding Phase 2 clinical trial. It is the first trial designed to evaluate ateganosine's anti-tumor activity when followed by PD-(L)1 inhibition. The trial is testing the hypothesis that low doses of ateganosine administered prior to cemiplimab (Libtayo®) will enhance and prolong immune response in patients with advanced NSCLC who previously did not respond or developed resistance and progressed after first-line treatment regimen containing another checkpoint inhibitor. The trial design has two primary objectives: (1) to evaluate the safety and tolerability of ateganosine administered as an anticancer compound and a priming immune activator (2) to assess the clinical efficacy of ateganosine using overall response rate (ORR) as the primary clinical endpoint. The expansion of the study will assess ORR in advanced NSCLC patients receiving third line (3L) therapy who were resistant to previous checkpoint inhibitor treatments (CPI) and chemotherapy. Treatment with ateganosine followed by cemiplimab (Libtayo®) has been generally well-tolerated to date in a heavily pre-treated population. For more information on this Phase 2 trial, please visit using the identifier NCT05208944. About MAIA Biotechnology, Inc. MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit Forward Looking Statements MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as "may," "might," "will," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "future," "potential," or "continue," and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, "MAIA," "Company," "we," "our," and "us" refers to MAIA Biotechnology, Inc. and its subsidiaries. View source version on Contacts Investor Relations Contact +1 (872) 270-3518ir@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
